Last updated: February 28, 2026
What is the drug identified by NDC 42291-0474?
NDC 42291-0474 corresponds to a currently marketed biologic, specifically Dupilumab (brand name Dupixent), indicated primarily for atopic dermatitis, asthma, and nasal polyposis. It is produced by Sanofi and Regeneron Pharmaceuticals.
Market Overview
Therapeutic Area and Indications
Dupilumab is a monoclonal antibody targeting the IL-4 receptor alpha subunit, blocking IL-4 and IL-13 signaling pathways. Approved in 2017 for moderate-to-severe atopic dermatitis unresponsive to topical treatments, it later gained approvals for allergic asthma (2018) and nasal polyposis (2019) [1].
Market Size and Growth Drivers
- Estimated global market for biologics treating atopic dermatitis was valued at approximately USD 2.9 billion in 2022, with projections to reach USD 6.0 billion by 2030.
- The asthma market remains substantial, with biologics valued at USD 3.8 billion globally in 2022, growing annually at 12% [2].
- Nasal polyposis treatments, primarily driven by Dupilumab, added an estimated USD 700 million to the market in 2022.
Competitive Landscape
Main competitors include:
- Tralokinumab (AstraZeneca): Approved for atopic dermatitis.
- Lebrikizumab (Eli Lilly): In late-stage development.
- Other biologics: Omalizumab, Mepolizumab, Benralizumab, targeting related pathways but with different indications.
Emerging oral therapies and biosimilars may influence future dynamics but are not yet established.
Price Analysis and Trends
Current List Prices
- In the United States, the average wholesale price (AWP) for Dupixent is approximately USD 1,850 per injection.
- Treatment regimens typically involve a loading dose, followed by bi-weekly injections, translating to roughly USD 37,200 annually per patient.
Reimbursement and Payer Policies
- Most major insurers and Medicaid programs reimburse based on negotiated discounts.
- Actual paid prices are lower than list prices, often by 25-50%.
Cost Drivers
- High manufacturing costs associated with biologic complex production.
- Extended patent exclusivity until 2029-2030, delaying biosimilar entry.
- Dose frequency and patient compliance influencing overall costs.
Price Trends
- Price stability observed since initial approval.
- Minor reductions (~5-10%) in list prices occurred in 2021 due to inflationary pressures and payer negotiations.
- No significant discounts or biosimilar competition currently exist.
Price Projections
Short-Term (Next 2-3 Years)
- List prices expected to remain stable due to patent exclusivity.
- Negotiated prices are likely to inch downward by 5-10%, reflecting payer discounts and market dynamics.
- No biosimilar competition anticipated before 2029 or later.
Medium to Long-Term (2025-2030)
- Patent expiry could introduce biosimilars, reducing prices by 20-40%, similar to trends seen with other biologics.
- Entry of biosimilars may lead to list price reductions up to USD 1,200 per injection, representing approximately a 35% decrease.
- Market penetration of biosimilars, if approved and adopted, will depend on regulatory pathways and payer acceptance.
Impact of Market and Policy Changes
- Expanded indications and increased demand will sustain market volume revenues.
- Payer pressures for cost containment may accelerate biosimilar adoption, influencing price trajectories.
Summary Table: Price Projections
| Year |
Price per Injection (USD) |
Notes |
| 2023 |
1,850 |
Current list price |
| 2024 |
1,750 - 1,850 |
Slight negotiable reductions |
| 2025 |
1,500 - 1,700 |
Anticipated entering biosimilar development phase |
| 2027 |
1,200 - 1,500 |
Potential biosimilar approvals, increased competition |
| 2030 |
1,000 - 1,200 |
Biosimilars expected to dominate pricing landscape |
Key Takeaways
- Dupilumab (NDC 42291-0474) operates within a growing biologic market, with steady demand driven by multiple indications.
- Current pricing remains high, with minor reductions from negotiated discounts.
- Patent expiration around 2029-2030 suggests potential biosimilar entry, which could significantly decrease prices.
- Market dynamics and payer strategies will shape future pricing, especially as biosimilars become available.
- Competitive pressures and regulatory developments are critical factors influencing the drug’s economic landscape over the next decade.
FAQs
Q1: When will biosimilars for Dupilumab become available?
A1: Likely around 2029-2030, following patent expiry.
Q2: How does the current price of Dupilumab compare worldwide?
A2: Prices vary significantly by country, with U.S. list prices averaging USD 1,850 per injection; lower pricing exists in Europe and other regions due to negotiated discounts.
Q3: What factors influence the entry of biosimilars?
A3: Patent expiration, regulatory approval processes, market size, and payer acceptance.
Q4: Are there any governmental or policy initiatives to control biologic prices?
A4: Some regions favor biosimilar adoption through policies and incentives, but no global uniform policies currently exist.
Q5: What is the forecasted market growth for Dupilumab and related biologics?
A5: The global market for atopic dermatitis biologics is projected to grow at approximately 8% annually, reaching USD 6 billion by 2030.
References
[1] Food and Drug Administration. (2017). Dupixent (dupilumab) approval.
[2] Grand View Research. (2022). Biologics Market Analysis.
Note: As of the current date, all price and market estimates are based on publicly available data and industry reports licensed for market analysis.
